Implementing Patients´ Competence in Oral Breast Cancer Therapy

Metastatic Breast Cancer Clinical Trial

— IMPACT  

Official title:

A Randomized, Controlled Study of Standardized Patient Coaching Versus Patient Management According to Local Practice for Patients With Hormone Receptor Positive HER2 Negative Metastatic Breast Cancer Treated With Abemaciclib

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04030728
• Other study ID #: OMC2018/01
• Status: Not yet recruiting
• Start date: March 2020
• Est. completion date: December 2021

Study information

• Verified date: January 2020
• Source: Onco Medical Consult GmbH
• Contact: Jenny Palmrich
• Phone: 0049 69 560056 182
• Email: jenny.palmrich[@]chop-studien.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the IMPACT - Implementing Patients' competence in oral breast cancer therapy - study is to evaluate the effectiveness of a standardized patient education and coaching and optional eMBSR for therapy management provided by specially trained oncology nurses regarding persistence rate, side effects management and unplanned therapy interruptions in outpatient oncology care for patients under Abemaciclib treatment.

Description:

Breast cancer therapy has advanced by far over the last decade. Introduction of novel therapies as well as the introduction of mammography screening are thought to have reduced mortality over the last decade. More women are treated on an individual basis, trying to avoid toxic and non-effective therapies.

However, every year about 18.000 women are diagnosed with metastastic breast cancer in Germany. Breast cancer remains one of the main reasons for deaths among women and is the main reason for death due to cancer in younger women.

Once a tumor is metastasized, well balanced treatment decisions have to be made to take both into consideration, a high chance of tumor control and a low risk for side effects. Especially in the metastatic setting symptom control and quality of life need to be in the focus of the therapy and patient care.

Modern anticancer strategies are designed against specific molecular targets with the goal of sparing normal, non-neoplastic tissues. Choosing specific molecular targets, however, is problematic. CDK4/6 (Cyclin dependent kinase 4 and 6) are important candidate targets for therapeutic intervention.

Traditionally, anticancer therapy has been dominated by intravenous drug therapy. However, oral agents, like CDK4/6 inhibitors, provide an attractive approach to this kind of treatment and use of oral treatments is increasing. Currently, there are three CDK4/6 inhibitors that have reached clinical practice in the management of ER+ HER2− advanced disease. One of them is Ademaciclib which is approved in the US since September 2017 for "adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient's hormones".

Oral agents for cancer treatment are increasingly prescribed due to their benefits. However, this type of therapy requires a high level of self-management competence by the patient. A standardized patient education provided by physicians and oncology nurses may influence the handling of the oral agents in a positive way regarding side effects and unplanned therapy interruptions.

When it comes to oral agents, the place of treatment is the patients' home. In this treatment setting, correct treatment management cannot be utilized without identifying a patient's needs to be empowered to become an expert of his/her treatment because cancer therapies are commonly difficult to handle and the medication often shows a high risk of side effects and interactions with other drugs. Care providers are challenged by the question of how mostly elderly and multimorbid patients and their supporting relatives can be enabled with essential competencies to manage their treatment by themselves. Before patients start their cancer therapy, they are usually provided with information about the treatment by their physician. However, patients often feel overwhelmed by all the details in this stressful situation and tend to have a reduced capacity to assimilate complex information. Education and additional support at the beginning and in the course of the treatment can be a useful approach for patients to better handle this situation.

Recent studies showed the positive impact of supportive care programs on patients provided by nurses. Patient-focused motivation techniques and education performed by nurses are suitable to strengthen the patients' understanding of risks and benefits from the anti-cancer treatment and oral agents. These care programs can prevent an incorrect medication intake due to misunderstandings, lead to a decrease of treatment-related symptoms like pain and fatigue and reduce critical events. In addition, patient education can facilitate supportive care through a better communication between patient and health care provider and may advance the early detection of adverse toxicity events and foster rapid symptom management.

Mindfulness based stress reduction (MBSR) shows a positive effect on mental health in breast cancer patients. The evidence confirms that MBSR reduces anxiety, depressiveness and stress of breast cancer patients and increases the health-related quality of life. A key ingredient to reduce the damaging effects of chronic stress, reducing distress, and improving quality of life is to have patients engage in behaviors that decrease sympathetic and increase parasympathetic arousal. Studies show that MBSR have a positive effect on many systems in our body and create fundamental changes in the way the brain functions. MBSR can affect neurotransmitters (i.e. glutamate, GABA) and neuromodulators (i.e. dopamine, serotonin, epinephrine), which are essential in maintaining a healthy balance between sympathetic and parasympathetic arousal, therefore, helping to manage the stress response.

The aim of the IMPACT - Implementing Patients' competence in oral breast cancer therapy - study is to evaluate the effectiveness of a standardized patient education and coaching and optional eMBSR for therapy management provided by specially trained oncology nurses regarding persistence rate, side effects management and unplanned therapy interruptions in outpatient oncology care for patients under Abemaciclib treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 212
• Est. completion date: December 2021
• Est. primary completion date: September 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult breast cancer patients (age =18 years).

• Patients with HR+, HER2- advanced or metastatic breast cancer proven by clinical measures (i. e. standard imaging) whose disease has progressed after hormonal therapy in combination with fulvestrant, or alone in women whose disease has progressed after hormone therapy and prior chemotherapy (advanced disease must not be amenable to resection with curative intent).

• Patients treated with Abemaciclib according to the SmPC and each center´s medical practice.

• Informed consent prior to onset of documentation.

Exclusion Criteria:

• Patients with serious preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).

• Females who are pregnant or lactating.

• Patients with active bacterial infections (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infections, or detectable viral infections (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.

• Patients with a personal history in the past 5 years of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.

• Patients with contraindications against Abemaciclib according to respective SmPC´s.

• Patients who are not eligible for observation due to severe comorbidities other then mentioned above or unavailability according to the treating physician.

Related Conditions & MeSH terms

• Advanced Breast Cancer
• Breast Neoplasms
• Metastatic Breast Cancer

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Onco Medical Consult GmbH	Eli Lilly and Company, Institut fuer Frauengesundheit

References & Publications (25)

Banna GL, Collovà E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferraù F. Anticancer oral therapy: emerging related issues. Cancer Treat Rev. 2010 Dec;36(8):595-605. doi: 10.1016/j.ctrv.2010.04.005. Epub 2010 Jun 8. Review. — View Citation

Bock K, Heywang-Köbrunner S, Regitz-Jedermann L, Hecht G, Kääb-Sanyal V. [Mammography screening in Germany. Current results and future challenges]. Radiologe. 2014 Mar;54(3):205-10. doi: 10.1007/s00117-013-2581-7. German. — View Citation

Bordonaro S, Romano F, Lanteri E, Cappuccio F, Indorato R, Butera A, D'Angelo A, Ferraù F, Tralongo P. Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy. Patient Prefer Adherence. 2014 Jun 25;8:917-23. doi: 10.2147/PPA.S62666. eCollection 2014. — View Citation

Campbell CP. An oral cancer therapy nurse navigator role. Can Nurse. 2016 Apr;112(3):26-7. — View Citation

Carlson LE, Doll R, Stephen J, Faris P, Tamagawa R, Drysdale E, Speca M. Randomized controlled trial of Mindfulness-based cancer recovery versus supportive expressive group therapy for distressed survivors of breast cancer. J Clin Oncol. 2013 Sep 1;31(25):3119-26. doi: 10.1200/JCO.2012.47.5210. Epub 2013 Aug 5. Erratum in: J Clin Oncol. 2014 Nov 10;32(32):3686-7. — View Citation

Chaoul A, Milbury K, Sood AK, Prinsloo S, Cohen L. Mind-body practices in cancer care. Curr Oncol Rep. 2014 Dec;16(12):417. doi: 10.1007/s11912-014-0417-x. Review. — View Citation

Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8 Suppl 1:S41-53. Review. — View Citation

Cramer H, Lauche R, Paul A, Dobos G. Mindfulness-based stress reduction for breast cancer-a systematic review and meta-analysis. Curr Oncol. 2012 Oct;19(5):e343-52. doi: 10.3747/co.19.1016. — View Citation

Eisemann N, Waldmann A, Katalinic A. Epidemiology of Breast Cancer - Current Figures and Trends. Geburtshilfe Frauenheilkd. 2013 Feb;73(2):130-135. — View Citation

Fasching PA, Brucker SY, Fehm TN, Overkamp F, Janni W, Wallwiener M, Hadji P, Belleville E, Häberle L, Taran FA, Lüftner D, Lux MP, Ettl J, Müller V, Tesch H, Wallwiener D, Schneeweiss A. Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. Geburtshilfe Frauenheilkd. 2015 Jan;75(1):41-50. — View Citation

Hölzel BK, Carmody J, Vangel M, Congleton C, Yerramsetti SM, Gard T, Lazar SW. Mindfulness practice leads to increases in regional brain gray matter density. Psychiatry Res. 2011 Jan 30;191(1):36-43. doi: 10.1016/j.pscychresns.2010.08.006. Epub 2010 Nov 10. — View Citation

Kolberg HC, Lüftner D, Lux MP, Maass N, Schütz F, Fasching PA, Fehm T, Janni W, Kümmel S. Breast Cancer 2012 - New Aspects. Geburtshilfe Frauenheilkd. 2012 Jul;72(7):602-615. — View Citation

Loehberg CR, Almstedt K, Jud SM, Haeberle L, Fasching PA, Hack CC, Lux MP, Thiel FC, Schrauder MG, Brunner M, Bayer CM, Hein A, Heusinger K, Heimrich J, Bani MR, Renner SP, Hartmann A, Beckmann MW, Wachter DL. Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. Breast Cancer Res Treat. 2013 Apr;138(3):899-908. doi: 10.1007/s10549-013-2460-y. Epub 2013 Mar 12. — View Citation

Maass N, Schütz F, Fasching PA, Fehm T, Janni W, Kümmel S, Kolberg HC, Lüftner D, Wallwiener M, Lux MP. Breast Cancer Update 2014 - Focus on the Patient and the Tumour. Geburtshilfe Frauenheilkd. 2015 Feb;75(2):170-182. — View Citation

Matchim Y, Armer JM, Stewart BR. Mindfulness-based stress reduction among breast cancer survivors: a literature review and discussion. Oncol Nurs Forum. 2011 Mar;38(2):E61-71. doi: 10.1188/11.ONF.E61-E71. Review. — View Citation

May P, Figgins B. Oral anticancer therapy: a comprehensive assessment of patient perceptions and challenges. J Community Support Oncol. 2016 Mar;14(3):112-6. doi: 10.12788/jcso.0226. — View Citation

Molassiotis A, Brearley S, Saunders M, Craven O, Wardley A, Farrell C, Swindell R, Todd C, Luker K. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol. 2009 Dec 20;27(36):6191-8. doi: 10.1200/JCO.2008.20.6755. Epub 2009 Nov 16. — View Citation

Musial F, Büssing A, Heusser P, Choi KE, Ostermann T. Mindfulness-based stress reduction for integrative cancer care: a summary of evidence. Forsch Komplementmed. 2011;18(4):192-202. doi: 10.1159/000330714. Epub 2011 Aug 8. Review. — View Citation

Piet J, Würtzen H, Zachariae R. The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and survivors: a systematic review and meta-analysis. J Consult Clin Psychol. 2012 Dec;80(6):1007-20. doi: 10.1037/a0028329. Epub 2012 May 7. Review. — View Citation

Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol. 2010 Nov;76(2):133-41. doi: 10.1016/j.critrevonc.2009.11.001. Epub 2009 Dec 24. — View Citation

Shennan C, Payne S, Fenlon D. What is the evidence for the use of mindfulness-based interventions in cancer care? A review. Psychooncology. 2011 Jul;20(7):681-97. doi: 10.1002/pon.1819. Epub 2010 Aug 4. Review. — View Citation

Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, Lennes IT, Dahlin CM, Pirl WF. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011 Jun 10;29(17):2319-26. doi: 10.1200/JCO.2010.32.4459. Epub 2011 May 9. — View Citation

Wadler S. Perspectives for cancer therapies with cdk2 inhibitors. Drug Resist Updat. 2001 Dec;4(6):347-67. Review. — View Citation

Würtzen H, Dalton SO, Elsass P, Sumbundu AD, Steding-Jensen M, Karlsen RV, Andersen KK, Flyger HL, Pedersen AE, Johansen C. Mindfulness significantly reduces self-reported levels of anxiety and depression: results of a randomised controlled trial among 336 Danish women treated for stage I-III breast cancer. Eur J Cancer. 2013 Apr;49(6):1365-73. doi: 10.1016/j.ejca.2012.10.030. Epub 2012 Dec 19. — View Citation

Zainal NZ, Booth S, Huppert FA. The efficacy of mindfulness-based stress reduction on mental health of breast cancer patients: a meta-analysis. Psychooncology. 2013 Jul;22(7):1457-65. doi: 10.1002/pon.3171. Epub 2012 Sep 7. Review. — View Citation

* Note: There are 25 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	(Potential) difference in persistence rate after 24 weeks of Abemaciclib therapy in both study arms.	The primary objective of this study is to evaluate both study arms regarding the (potential) effect of patient management according to local routine versus continuous standardized patient education and coaching using the MOATT on persistence rate within the first 24 weeks of Abemaciclib treatment.	24 weeks
Secondary	Patient decided interruptions	Total time of patient decided interruptions in days during 24 weeks of Abemaciclib therapy in both study arms.	24 weeks
Secondary	eMSBR	The effect of eMSBR after 24 weeks of Abemaciclib therapy.	24 weeks
Secondary	Quality of life assessed by the FACT-B (Version 4.0) questionnaires.	After weeks 2, 6, 12, 18 and 24, quality of Life (QoL) will be assessed by the FACT-B (Version 4.0) questionnaires.	24 weeks
Secondary	Patient distress assessed via distress thermometer.	After weeks 2, 6, 12, 18 and 24, patient distress will be assessed via distress thermometer.	24 weeks
Secondary	To assess patient reported self-efficacy: patient diary	Self-efficacy will be patient reported and surveyed through a patient dairy.	24 weeks
Secondary	To assess patient reported side-effects.	Type and duration of side-effects will be patient reported and surveyed through a patient dairy.	24 weeks
Secondary	To assess patient reported health related stress.	Health related stress will be patient reported and surveyed via distress thermometer questionnaire.	24 weeks
Secondary	To assess patient reported therapy related knowledge.	Therapy related knowledge will be surveyed via MOATT (MASCC Oral Agent Teaching Tool).	24 weeks
Secondary	Incidence of therapy interruptions.	Amount of relevant events will be surveyed through patient self-reporting via patient diary.	24 weeks
Secondary	Duration of therapy interruptions.	Relevant events (in days) will be surveyed through patient self-reporting via patient diary.	24 weeks
Secondary	Safety and tolerability of Abemaciclib treatment: NCI Common Toxicity Criteria Version 5.0	Incidence of adverse events and serious adverse events will be reported according to NCI Common Toxicity Criteria Version 5.0.	24 weeks
Secondary	Efficacy between the two study arms at week 24 in routine clinical practice as assessed by Progression free survival rate (PFS).	Progression free survival (PFS) rate at 24 weeks of therapy. PFS is defined as time interval from start of therapy until progressive proven with clinical measures according to expertise and daily clinical routine or death from any cause, whichever comes first.	24 weeks
Secondary	Efficacy between the two study arms at week 24 in routine clinical practice as assessed by Overall survival rate (OS).	Overall survival (OS) rate at 24 months is defined as the time to death from therapy start of Abemaciclib.	24 weeks